Virginia Economic Review

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

John Newby is the CEO of Virginia Bio, the nonprofit statewide trade association that serves and promotes the life sciences industry in Virginia.

John Newby is the CEO of Virginia Bio, the nonprofit statewide trade association that serves and promotes the life sciences industry in Virginia.

Eric Arocho is associate vice president at Eli Lilly and Company and the site lead on the company’s facility in Goochland County, announced last year.

In October 2025, shovels went into the ground in Elkton, marking the start of a $3 billion pharmaceutical expansion project that will add 400,000 square feet to Merck’s existing campus.

A pharmaceutical manufacturing innovation that came out of a Virginia university is changing the way medicines are made. The Commonwealth’s universities and the rest of its biopharma research community are making sure Virginia is ready to make the medicines of the future.

The Greater Richmond region is in the middle of the greatest population growth in its history.

In October 2025, shovels went into the ground in Elkton, marking the start of a $3 billion pharmaceutical expansion project that will add 400,000 square feet to Merck’s existing campus.

Dave Maraldo is the senior vice president of Human Health Manufacturing Operations at Merck, one of the five largest biopharmaceutical companies in the world.

A lot changed in Virginia’s life sciences industry in the space of about a month last fall. Between Sept. 16 and Oct. 20, biopharmaceutical manufacturing giants Eli Lilly and Company, AstraZeneca, and Merck & Co.

Merck’s expansion at its Rockingham County site, announced in late 2025, represents the continuation of a long, mutually beneficial tenure in the Commonwealth.

A lot changed in Virginia’s life sciences industry in the space of about a month last fall. Between Sept. 16 and Oct. 20, biopharmaceutical manufacturing giants Eli Lilly and Company, AstraZeneca, and Merck & Co.

Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.

A pharmaceutical manufacturing innovation that came out of a Virginia university is changing the way medicines are made. The Commonwealth’s universities and the rest of its biopharma research community are making sure Virginia is ready to make the medicines of the future.

Would more men try to prevent unintended pregnancies if their choices for contraception went beyond a condom or vasectomy?

Food and beverage and pharmaceutical companies rely on Virginia’s cold chain infrastructure to succeed.

New or expanding companies want to know that they will be able to hire workers with the skills they need. While outside training providers offer established but generic faculty, facilities, and programs, in-house solutions allow for customization but require significant investment.